

1 **Regional replacement of SARS-CoV-2 variant BA.1 with BA.2 as observed through**
2 **wastewater surveillance**

3
4
5
6

Alexandria B. Boehm^{1*}, Bridgette Hughes², Marlene K. Wolfe³, Bradley J. White², Dorothea Duong², Vikram Chan-Herur²

7 1. Department of Civil & Environmental Engineering, Stanford University, 473 Via Ortega,
8 Stanford, CA, USA, 94305


9 2. Verily Life Sciences, South San Francisco, CA, USA, 94080

10 3. Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory
11 University, 1518 Clifton Rd, Atlanta, GA, USA, 30322

12
13 * Corresponding author: Alexandria Boehm, Dept Civil and Environmental Engineering, Stanford
14 University, Stanford, California, USA, 94305, aboehm@stanford.edu, 650-724-9128

15
16

Graphical Abstract



17
18
19

20 **Abstract**

21
22 An understanding of circulating SARS-CoV-2 variants can inform pandemic response, vaccine
23 development, disease epidemiology, and use of monoclonal antibody treatments. We developed
24 custom assays targeting characteristic mutations in SARS-CoV-2 variants Omicron BA.1 and
25 BA.2 and confirmed their sensitivity and specificity *in silico* and *in vitro*. We then applied these
26 assays to daily wastewater solids samples from eight publicly owned treatment works in the
27 greater Bay Area of California, USA, over four months to obtain a spatially and temporally
28 intensive data set. We documented regional replacement of BA.1 with BA.2 in agreement with,
29 and ahead of, clinical sequencing data. This study highlights the utility of wastewater
30 surveillance for real time tracking of SARS-CoV-2 variant circulation.

31 **Key words:** Omicron, wastewater, SARS-CoV-2, wastewater-based epidemiology

32
33 **Synopsis:** Wastewater surveillance was used to document regional emergence of SARS-CoV-
34 2 variant Omicron BA.2 ahead of clinical surveillance.
35

36 **Introduction**

37 Knowing when a new SARS-CoV-2 variant arrives locally is of utmost importance to pandemic
38 response in order to ensure a rapid response to new features of the virus. In late 2021, the
39 Omicron variant emerged in South Africa and quickly spread to Europe and then North America
40 during a period of time during which Delta was the dominant circulating variant. The Omicron
41 variant resulted in a virus more transmissible and less susceptible to therapeutics and vaccines
42 than previous lineages¹. Given these implications for public health, timely identification of its
43 introduction into a new community was critical. Variant identification is usually accomplished
44 through sequencing of clinical specimens, but the time between specimen collection, and the
45 return of sequencing information to public health officials is approximately two weeks. For
46 example, outbreak.info², a website that provides analysis and visualization of SARS-CoV-2
47 clinical sequences deposited in GISAID^{3,4}, stresses data are unreliable and incomplete during
48 the 1-2 week window preceding the query date.

49
50 Wastewater represents a biological composite sample from the contributing community. It
51 contains feces, urine, sputum, mucus, blood, vomitus, and any other excretion that goes down a
52 drain into the sewer network. Global investigations have illustrated that SARS-CoV-2 RNA
53 concentrations, whether measured by RT-QPCR or digital RT-PCR, or in the liquid or solid
54 phase of wastewater, correlates well with laboratory-confirmed incident COVID-19 cases in the
55 associated sewersheds⁵⁻⁸. A number of studies have illustrated that circulating or novel variants
56 can be identified in wastewater using RT-PCR assays that target a characteristic variant
57 mutation⁹⁻¹¹ and by sequencing SARS-CoV-2¹². We previously developed targeted RT-PCR
58 assays for characteristic mutations in Alpha, Mu, Lambda, Delta, and Omicron BA.1, and
59 showed that the concentrations of these mutations, normalized by a pan-SARS-CoV-2 N gene
60 target is strongly correlated to the fraction of clinical specimens classified as the associated
61 variant^{10,13} at two publicly owned treatment works (POTWs). Here, we extend that previous work

62 by developing and testing two new assays, one that targets characteristic mutations in the BA.2
63 sublineage of Omicron and another that targets a set of mutations present in both BA.1 and
64 BA.2, and then applying them to wastewater samples collected daily at eight POTW in the
65 greater Bay Area, California, USA. Results presented here were available publicly within 24
66 hours of sample collection via our website (wbe.stanford.edu), and these data allowed us to
67 observe near real-time regional replacement of BA.1 with BA.2.

68

69 **Materials and Methods**

70

71 **Characteristic spike mutation assay development.** Digital RT-PCR assays were designed to
72 target the BA.2 characteristic mutation LPPA24S (a 9 bp deletion), and a region of 5 adjacent
73 SNPs common to BA.1 and BA.2 (S477N,T478K,Q493R,Q498R,Y505H, hereafter S:477-505).
74 The del143-145 assay targeting a mutation present in BA.1 was developed in a similar manner
75 described elsewhere¹⁰. According to sequences deposited in GISAID and accessed via
76 outbreak.info (accessed 16 April 2022), the LPPA24S mutation is present in 92% of BA.2
77 genomes, including sublineages, (hereafter BA.2*) and 0.003% of BA.1 genomes, including
78 sublineages, (hereafter BA.1*) globally whereas the del143-145 mutation is present in 93%
79 BA.1* and 0% BA.2* genomes, globally (Table S1). Assays were developed *in silico* using
80 Primer3Plus (<https://primer3plus.com/>) (Table S2).

81

82 Primers and probe sequences (Table 1) were screened for specificity *in silico* using NCBI
83 BLAST, and then tested *in vitro* against various respiratory viruses and gRNA from wild-type
84 (WT) SARS-CoV-2 and its variants (see SI). Viral RNA was used undiluted as template in digital
85 droplet RT-PCR with mutation primer and probes. The concentration of gRNA used for *in vitro*
86 specificity testing was approximately 275 copies per well.

87

88 The sensitivity and specificity of the mutation assays were further tested by diluting target
89 variant gRNA (Table S1) in no (0 copies), low (100 copies), and high (10,000 copies)
90 background of WT SARS-CoV-2 gRNA.

91

92 **Wastewater samples.** Eight POTWs serving populations of the Greater Bay Area and
93 Sacramento, California, USA were included in the study. They serve between 66,000 and 1.5
94 million people; further descriptions are elsewhere.¹⁴

95

96 50 mL of settled solids was collected each day from each POTW between 1 January 2022 and
97 12 or 13 April 2022, during the period of time when Omicron BA.2 emerged in the region.

98 Detailed sample collection methods are provided elsewhere¹⁴ and in the SI. Samples were

99 immediately stored at 4°C and transported to the laboratory by a courier service where

100 processing began within 6 h of collection. Between 94 and 103 samples from each POTW

101 were included in the analysis (total of 810).

102

103 RNA was extracted from 10 replicate aliquots of each dewatered settled solids sample and PCR

104 inhibitors were removed¹⁴ (see SI). RNA was processed immediately to measure concentrations

105 of the N gene of SARS-CoV-2, the BA.1* characteristic mutation del143-145¹⁰, the BA.2*

106 characteristic mutation (LPPA24S), pepper mild mottle virus (PMMoV), and bovine coronavirus

107 (BCoV) recovery using digital droplet RT-PCR methods^{14,15}. The N gene target is present in all

108 variants and is a pan-SARS-CoV-2 gene target. PMMoV is highly abundant in human stool and

109 wastewater globally^{16,17} and is used as an internal recovery for the wastewater samples¹⁸.

110 BCoV was spiked into the samples and used as an additional recovery control; all samples were

111 required to have greater than 10% BCoV recovery. RNA extraction and PCR negative and

112 positive controls were included to ensure no contamination. Extracted RNA samples from one

113 POTW (SJ) were then stored at -80°C between 1 and 7 days before they were analyzed for

114 S:477-505 and the N gene. Each of the 10 replicate RNA extracts was run in its own well, and
115 the 10 wells were merged for analysis. Wastewater data are available publicly at the Stanford
116 Digital Repository (<https://doi.org/10.25740/cf848zx9249>); results below are reported as
117 suggested in the EMMI guidelines¹⁹.

118

119 **ddRT-PCR.** The ddRT-PCR methods applied to wastewater solids to measure PMMoV and
120 BCoV are provided in detail elsewhere¹⁴. The N gene and del143-145 mutation were
121 multiplexed along with an S gene assay (not reported herein). LPPA24S mutation was
122 multiplexed in an assay along with an influenza A and RSV N gene target (only LPPA24S
123 reported herein). The S:477-505 mutation was multiplexed with the N gene and a characteristic
124 mutation in Delta (not reported). Each 96-well PCR plate of wastewater samples included PCR
125 and extraction positive and negative controls. Additional details of the PCR methods are
126 provided in the SI.

127

128 QuantaSoft™ Analysis Pro Software (Bio-Rad, version 1.0.596) was used for thresholding. In
129 order for a sample to be recorded as positive, it had to have at least three positive droplets. For
130 the wastewater solid samples, three positive droplets across ten merged wells corresponds to a
131 concentration between ~500-1000 copies per g (cp/g); the range in values is a result of the
132 range in the equivalent mass of dry solids added to the wells.

133

134 Concentrations of RNA targets were converted to concentrations per dry weight of solids in units
135 of copies/g dry weight using dimensional analysis. Dry weight of dewatered solids was
136 determined by oven drying²⁰. The total error is reported as standard deviations and includes the
137 errors associated with the Poisson distribution and the variability among the 10 replicates.

138

139 **Variants present in regional clinical specimens.** The 7-d, centered, rolling average
140 proportion of clinical specimens sequenced from California classified as Omicon BA.1* and
141 BA.2* as a function of specimen collection data were acquired from GISAID^{3,4} on 21 April 2022.

142
143 **Statistics.** We normalized mutation concentrations by N gene concentrations to represent the
144 fraction of total SARS-CoV-2 RNA (represented by the N gene assay target which is conserved
145 across variants) that comes from the variant; hereafter referred to as relative mutation
146 concentration. We used Kendall's tau to test for associations between the 5-d trimmed
147 smoothed average relative concentrations and the proportion of clinical specimens assigned to
148 the corresponding variants as the two variables were not normally distributed (Shapiro Wilk test,
149 $p < 0.05$ for all). The daily measured relative concentration was matched to the 7-d, centered,
150 rolling average fraction of clinical specimens classified as the associated variant obtained from
151 GISAID. All analysis was carried in R Studio version 1.4.1106.

152

153

154 **Results and Discussion**

155 **Variant mutation assay specificity.** *In silico* analysis indicated no cross reactivity between
156 LPPA24S (targeting BA.2*) and S:477-505 (targeting BA.1* and BA.2*) assays and deposited
157 sequences in NCBI. When challenged against a respiratory virus panel and various non-target
158 SARS-CoV-2 variant gRNA no cross reactivity was observed; the assays amplified gRNA from
159 BA.2, and BA.1 and BA.2, respectively. Positive controls and NTCs run on sample plates were
160 positive and negative. When target gRNA was diluted into a background of low and high non-
161 target gRNA from WT SARS-CoV-2; measurements were similar when there was no, low, or
162 high background gRNA (Figure S1). Results indicate the new mutation assays are specific and
163 sensitive. Wolfe et al.¹⁰ showed the del143-145 (targeting BA.1) assay was sensitive and
164 specific.

165

166 **Variant RNA concentrations in wastewater solids.** All positive and negative controls were
167 positive and negative, respectively, indicating assays performed well and without contamination.
168 BCoV recoveries were higher than 10% and PMMoV concentrations within the expected range
169 for the POTW suggesting an efficient and acceptable recovery of RNA during RNA extraction
170 (Figure S2).

171

172 Across all eight POTWs a common pattern in N, del143-145, and LPPA24S concentrations is
173 observed. Between 1 Jan and late Feb to mid-March 2022, N and del143-145 concentrations
174 are approximately the same, and both decrease from 10^6 cp/g to 10^4 cp/g (Figure 1). The two
175 order of magnitude decrease is coincident with a decline in laboratory-confirmed incident
176 COVID-19 cases in the sewersheds after the winter Omicron surge in the region (case data not
177 shown). In late Feb to mid-March until mid-April, both N and LPPA24S concentrations increase
178 from 10^3 cp/g to 10^5 cp/g, while del143-145 concentrations decrease from 10^4 cp/g to 10^2 cp/g
179 or non-detect. LPPA24S concentrations are similar to those of N at the POTWs during that
180 same time period.

181

182 The ratios del143-145/N and LPPA24S/N describe the concentrations of the mutations in
183 relation to a conserved gene target. As a mutation's relative concentration approaches 1, it
184 suggests that the variant associated with the mutation may be dominant in the wastewater.
185 Del143-145 relative concentration was a maximum and close to 1 at most POTWs at the
186 beginning of the time series (1 January 2022) and then fell to nearly 0 by mid-April 2022 (Figure
187 2). At the same time, LPPA24S relative concentration increased from 0 when it was first
188 measured to near 1 at all POTWs. Depending on POTW, the date on which the LPPA24S
189 relative concentration surpassed that of del143-145 ranged from 26 February to 19 March
190 (Table S3). This date was earliest (26 Feb) at Ocean, located in San Francisco, and latest at Gil

191 and Sac; the date is positively correlated with the distance from Ocean ($r = 0.9$, $p < 0.05$, $n = 8$)
192 suggesting a spatial pattern in BA.2* emergence. Regional replacement of BA.1* with BA.2*
193 appears to be complete at all POTWs by the end of the times series as the del143-145 relative
194 concentrations are close to 0 and LPPA24S relative concentrations approach 1. At times,
195 relative concentrations may exceed 1; this may be due to variability in the performance of the
196 digital RT-PCR assays. It is important to note that the relative concentrations do not incorporate
197 measurement error of the numerator or denominator.

198

199 At SJ, we measured the concentration of an additional set of adjacent mutations present in both
200 BA.1 and BA.2 (S:477-505) (Figure 1). S:477-505 concentrations agree well with the N
201 concentrations during a period of time when BA.1* was dominant (prior to mid-March) and when
202 BA.2* was dominant (thereafter).

203

204 del143-145 and LPPA24S relative concentrations at each POTW are positively and significantly
205 correlated with the fraction of clinical cases in California assigned as BA.1* and BA.2*,
206 respectively (Table S4). Tau between relative del143-145 concentrations and proportion of
207 cases assigned as BA.1* ranged from 0.51 at Gil to 0.81 at SAC (median tau = 0.68, all $p < 10^{-7}$,
208 $n = 94-103$). Tau between relative LPPA24S concentrations and proportion of cases assigned
209 as BA.2* ranged from 0.67 at Gil to 0.90 at SAC (median tau = 0.75, all $p < 10^{-5}$, $n = 58-62$). Tau
210 values were similar when calculated using raw relative concentrations (see SI). State level
211 clinical data suggest proportion of cases caused by BA.2* exceeds that of BA.1* after 21 March
212 (Figure 3), later than any wastewater suggests this occurred regionally. Ideally, these analyses
213 should be carried out using data on clinical variants in the sewersheds of the eight POTWs, but
214 such data is not readily available, so we had to rely on state-level data.

215

216 State-level clinical sample sequencing data on variant occurrence is typically 1-2 weeks delayed
217 owing to the time required for laboratory processing and reporting. In addition, there can be
218 large uncertainties in the proportion estimates preceding the data for which the most recent data
219 are available. This is illustrated in Figure 3 where we highlight the approximate time period for
220 which data were incomplete on 14 April 2022, when wastewater measurements for the last date
221 in our data series (12 or 13 April 2022) were available publicly on our website
222 (wbe.stanford.edu). During this same time period, wastewater data suggest BA.2* is near 100%
223 and BA.1* is near 0%, which a week later (when data were downloaded from GISAID on 21
224 April 2022) was confirmed by clinical sequencing data. This highlights an important advantage
225 of using wastewater surveillance for variant tracking.

226

227 Real-time estimates of variant abundance with high spatial resolution, such as those from
228 wastewater surveillance, could allow clinicians and regulators to identify the most effective
229 treatment for a particular community. The monoclonal antibody therapy sotrovimab provides a
230 recent and practical example. Sotrovimab was granted emergency use authorization by the US
231 FDA for treatment of infection by variants including BA.1, but not BA.2. As BA.2 took over, its
232 use was discontinued by multi-state HHS region blocks, informed by clinical sequencing data.
233 While sotrovimab was allowed for use in California until March 30, our data suggest BA.2
234 became the dominant variant in the Bay Area weeks prior, but before BA.2 had taken over all of
235 California and HHS region 9. Real-time wastewater variant estimates could have allowed the
236 drug's use to be targeted spatially and temporally to maximize effectiveness.

237

238 **Acknowledgements.** This work is supported by the CDC Foundation. Numerous people
239 contributed to sample collection and case data acquisition, including Srividhya Ramamoorthy
240 (Sac), Michael Cook (Sac), Ursula Bigler (Sac), James Noss (Sac), Lisa C. Thompson (Sac),
241 Payak Sarkar (SJ), Noel Enoki (SJ), and Amy Wong (SJ), Lily Chan (Ocean), the Oceanside

242 plant operations personnel, Karin North (PA), Armando Guizar (PA), Saeid Vaziry (Gil), Chris
243 Vasquez (Gil), Alo Kauravlla (Sun), Maria Gawat (SVCW), Tiffany Ishaya (SVCW), and Jeromy
244 Miller (Dav). This study was performed on the ancestral and unceded lands of the Muwekma
245 Ohlone people. We pay our respects to them and their Elders, past and present, and are
246 grateful for the opportunity to live and work here. The graphic abstract was made using
247 Biorender (biorender.com).

248

249 **Supporting Information.** Additional methods, Tables S1-S5, Figures S1-S3. This paper has
250 been previously submitted to medRxiv, a preprint server for Health Sciences. The preprint can
251 be cited as: XXXX (to be provided).

252

253 **Competing Interests.** BH, DD, VC-H and BW are employees of Verily Life Sciences.

254

255

256

References

- 257 (1) Viana, R.; Moyo, S.; Amoako, D. G.; Tegally, H.; Scheepers, C.; Althaus, C. L.; Anyaneji,
258 U. J.; Bester, P. A.; Boni, M. F.; Chand, M.; Choga, W. T.; Colquhoun, R.; Davids, M.;
259 Deforche, K.; Doolabh, D.; du Plessis, L.; Engelbrecht, S.; Everatt, J.; Giandhari, J.;
260 Giovanetti, M.; Hardie, D.; Hill, V.; Hsiao, N.-Y.; Iranzadeh, A.; Ismail, A.; Joseph, C.;
261 Joseph, R.; Koopile, L.; Kosakovsky Pond, S. L.; Kraemer, M. U. G.; Kuate-Lere, L.;
262 Laguda-Akingba, O.; Lesetedi-Mafoko, O.; Lessells, R. J.; Lockman, S.; Lucaci, A. G.;
263 Maharaj, A.; Mahlangu, B.; Maponga, T.; Mahlakwane, K.; Makatini, Z.; Marais, G.;
264 Maruapula, D.; Masupu, K.; Matshaba, M.; Mayaphi, S.; Mbhele, N.; Mbulawa, M. B.;
265 Mendes, A.; Mlisana, K.; Mnguni, A.; Mohale, T.; Moir, M.; Moruisi, K.; Mosepele, M.;
266 Motsatsi, G.; Motswaledi, M. S.; Mphoyakgosi, T.; Msomi, N.; Mwangi, P. N.; Naidoo, Y.;
267 Ntuli, N.; Nyaga, M.; Olubayo, L.; Pillay, S.; Radibe, B.; Ramphal, Y.; Ramphal, U.; San,
268 J. E.; Scott, L.; Shapiro, R.; Singh, L.; Smith-Lawrence, P.; Stevens, W.; Strydom, A.;
269 Subramoney, K.; Tebeila, N.; Tshiabuila, D.; Tsui, J.; van Wyk, S.; Weaver, S.; Wibmer,
270 C. K.; Wilkinson, E.; Wolter, N.; Zarebski, A. E.; Zuze, B.; Goedhals, D.; Preiser, W.;
271 Treurnicht, F.; Venter, M.; Williamson, C.; Pybus, O. G.; Bhiman, J.; Glass, A.; Martin, D.
272 P.; Rambaut, A.; Gaseitsiwe, S.; von Gottberg, A.; de Oliveira, T. Rapid Epidemic
273 Expansion of the SARS-CoV-2 Omicron Variant in Southern Africa. *Nature* **2022**, *603*
274 (7902), 679–686. <https://doi.org/10.1038/s41586-022-04411-y>.
275 (2) Mullen, J. L.; Tsueng, G.; Latif, A. A.; Alkuzweny, M.; Cano, M.; Haag, E.; Zhou, J.; Zeller,
276 M.; Hufbauer, E.; Matteson, N.; Andersen, K. G.; Wu, C.; Su, A. I.; Gangavarapu, K.;
277 Hughes, L. D. <https://outbreak.info/>.
278 (3) Elbe, S.; Buckland-Merrett, G. Data, Disease and Diplomacy: GISAID's Innovative
279 Contribution to Global Health. *Global Challenges* **2017**, *1* (1), 33–46.
280 <https://doi.org/10.1002/gch2.1018>.
281 (4) Shu, Y.; McCauley, J. GISAID: Global Initiative on Sharing All Influenza Data – from
282 Vision to Reality. *Eurosurveillance* **2017**, *22* (13). [https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494)
283 [7917.ES.2017.22.13.30494](https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494).
284 (5) Peccia, J.; Zulli, A.; Brackney, D. E.; Grubaugh, N. D.; Kaplan, E. H.; Casanovas-
285 Massana, A.; Ko, A. I.; Malik, A. A.; Wang, D.; Wang, M.; Warren, J. L.; Weinberger, D.
286 M.; Omer, S. B. SARS-CoV-2 RNA Concentrations in Primary Municipal Sewage Sludge
287 as a Leading Indicator of COVID-19 Outbreak Dynamics. *Nature Biotechnology* **2020**, *38*,
288 1164–1167.
289 (6) Feng, S.; Roguet, A.; McClary-Gutierrez, J. S.; Newton, R. J.; Kloczko, N.; Meiman, J. G.;
290 McLellan, S. L. Evaluation of Sampling, Analysis, and Normalization Methods for SARS-
291 CoV-2 Concentrations in Wastewater to Assess COVID-19 Burdens in Wisconsin
292 Communities. *ACS ES&T Water* **2021**, *1* (8), 1955–1965.
293 <https://doi.org/10.1021/acsestwater.1c00160>.
294 (7) Kim, S.; Kennedy, L. C.; Wolfe, M. K.; Criddle, C. S.; Duong, D. H.; Topol, A.; White, B.
295 J.; Kantor, R. S.; Nelson, K. L.; Steele, J. A.; Langlois, K.; Griffith, J. F.; Zimmer-Faust, A.
296 G.; McLellan, S. L.; Schussman, M. K.; Ammerman, M.; Wigginton, K. R.; Bakker, K. M.;
297 Boehm, A. B. SARS-CoV-2 RNA Is Enriched by Orders of Magnitude in Primary Settled
298 Solids Relative to Liquid Wastewater at Publicly Owned Treatment Works. *Environ. Sci.:*
299 *Water Res. Technol.* **2022**. <https://doi.org/10.1039/D1EW00826A>.
300 (8) Fernandez-Cassi, X.; Scheidegger, A.; Bänziger, C.; Cariti, F.; Corzon, A. T.;
301 Ganesanandamoorthy, P.; Lemaitre, J. C.; Ort, C.; Julian, T. R.; Kohn, T. Wastewater
302 Monitoring Outperforms Case Numbers as a Tool to Track COVID-19 Incidence
303 Dynamics When Test Positivity Rates Are High. *Water Research* **2021**, 117252.
304 <https://doi.org/10.1016/j.watres.2021.117252>.
305 (9) Lee, W. L.; Imakaev, M.; Armas, F.; McElroy, K. A.; Gu, X.; Duvall, C.; Chandra, F.;

- 306 Chen, H.; Leifels, M.; Mendola, S.; Floyd-O'Sullivan, R.; Powell, M. M.; Wilson, S. T.;
307 Berge, K. L. J.; Lim, C. Y. J.; Wu, F.; Xiao, A.; Moniz, K.; Ghaeli, N.; Matus, M.;
308 Thompson, J.; Alm, E. J. Quantitative SARS-CoV-2 Alpha Variant B.1.1.7 Tracking in
309 Wastewater by Allele-Specific RT-QPCR. *Environ. Sci. Technol. Lett.* **2021**, *8* (8), 675–
310 682. <https://doi.org/10.1021/acs.estlett.1c00375>.
- 311 (10) Wolfe, M. K.; Hughes, B.; Duong, D.; Chan-Herur, V.; Wigginton, W. K.; White, B. J.;
312 Boehm, A. B. Detection of SARS-CoV-2 Variants Mu, Beta, Gamma, Lambda, Delta,
313 Alpha, and Omicron in Wastewater Settled Solids Using Mutation-Specific Assays Is
314 Associated with Regional Detection of Variants in Clinical Samples. *Applied and*
315 *Environmental Microbiology* *0* (0), e00045-22. <https://doi.org/10.1128/aem.00045-22>.
- 316 (11) Yaniv, K.; Ozer, E.; Kushmaro, A. SARS-CoV-2 Variants of Concern, Gamma (P.1) and
317 Delta (B.1.617), Sensitive Detection and Quantification in Wastewater Employing Direct
318 RT-QPCR. *medRxiv* **2021**, 2021.07.14.21260495.
319 <https://doi.org/10.1101/2021.07.14.21260495>.
- 320 (12) Crits-Christoph Alexander; Kantor Rose S.; Olm Matthew R.; Whitney Oscar N.; Al-
321 Shayeb Basem; Lou Yue Clare; Flamholz Avi; Kennedy Lauren C.; Greenwald Hannah;
322 Hinkle Adrian; Hetzel Jonathan; Spitzer Sara; Koble Jeffery; Tan Asako; Hyde Fred;
323 Schroth Gary; Kuersten Scott; Banfield Jillian F.; Nelson Kara L.; Pettigrew Melinda M.
324 Genome Sequencing of Sewage Detects Regionally Prevalent SARS-CoV-2 Variants.
325 *mBio* *12* (1), e02703-20. <https://doi.org/10.1128/mBio.02703-20>.
- 326 (13) Yu, A.; Hughes, B.; Wolfe, M.; Leon, T.; Duong, D.; Rabe, A.; Kennedy, L.; Ravuri, S.;
327 White, B.; Wigginton, K. R.; Boehm, A.; Vugia, D. Estimating Relative Abundance of Two
328 SARS-CoV-2 Variants through Wastewater Surveillance at Two Large Metropolitan Sites.
329 *Emerging Infect. Dis.* **2022**, *28* (5), 940–947.
- 330 (14) Wolfe, M. K.; Topol, A.; Knudson, A.; Simpson, A.; White, B.; Duc, V.; Yu, A.; Li, L.;
331 Balliet, M.; Stoddard, P.; Han, G.; Wigginton, K. R.; Boehm, A. High-Frequency, High-
332 Throughput Quantification of SARS-CoV-2 RNA in Wastewater Settled Solids at Eight
333 Publicly Owned Treatment Works in Northern California Shows Strong Association with
334 COVID-19 Incidence. *mSystems* **2021**, *0* (0), e00829-21.
335 <https://doi.org/10.1128/mSystems.00829-21>.
- 336 (15) Topol, A.; Wolfe, M.; White, B.; Wigginton, K.; Boehm, A. High Throughput SARS-COV-2,
337 PMMOV, and BCoV Quantification in Settled Solids Using Digital RT-PCR. *protocols.io*
338 **2021**.
- 339 (16) Kitajima, M.; Sassi, H. P.; Torrey, J. R. Pepper Mild Mottle Virus as a Water Quality
340 Indicator. *npj Clean Water* **2018**, *1* (1), 19. <https://doi.org/10.1038/s41545-018-0019-5>.
- 341 (17) Symonds, E. M.; Nguyen, K. H.; Harwood, V. J.; Breitbart, M. Pepper Mild Mottle Virus: A
342 Plant Pathogen with a Greater Purpose in (Waste)Water Treatment Development and
343 Public Health Management. *Water Research* **2018**, *144*, 1–12.
344 <https://doi.org/10.1016/j.watres.2018.06.066>.
- 345 (18) McClary-Gutierrez, J. S.; Aanderud, Z. T.; Al-faliti, M.; Duvallet, C.; Gonzalez, R.;
346 Guzman, J.; Holm, R. H.; Jahne, M. A.; Kantor, R. S.; Katsivelis, P.; Kuhn, K. G.; Langan,
347 L. M.; Mansfeldt, C.; McLellan, S. L.; Mendoza Grijalva, L. M.; Murnane, K. S.; Naughton,
348 C. C.; Packman, A. I.; Paraskevopoulos, S.; Radniecki, T. S.; Roman, F. A.; Shrestha, A.;
349 Stadler, L. B.; Steele, J. A.; Swalla, B. M.; Vikesland, P.; Wartell, B.; Wilusz, C. J.; Wong,
350 J. C. C.; Boehm, A. B.; Halden, R. U.; Bibby, K.; Delgado Vela, J. Standardizing Data
351 Reporting in the Research Community to Enhance the Utility of Open Data for SARS-
352 CoV-2 Wastewater Surveillance. *Environ. Sci.: Water Res. Technol.* **2021**, *7* (9), 1545–
353 1551. <https://doi.org/10.1039/D1EW00235J>.
- 354 (19) Borchardt, M. A.; Boehm, A. B.; Salit, M.; Spencer, S. K.; Wigginton, K. R.; Noble, R. T.
355 The Environmental Microbiology Minimum Information (EMMI) Guidelines: QPCR and
356 DPCR Quality and Reporting for Environmental Microbiology. *Environ. Sci. Technol.*

357 **2021**, *55* (15), 10210–10223. <https://doi.org/10.1021/acs.est.1c01767>.
358 (20) Topol, A.; Wolfe, M.; White, B.; Wigginton, K.; Boehm, A. High Throughput Pre-Analytical
359 Processing of Wastewater Settled Solids for SARS-CoV-2 RNA Analyses. *protocols.io*
360 **2021**.
361
362


363
364
365

Mutations		Sequence
LPPA24S	Forward	GCCACTAGTCTCTAGTCAGTGTG
	Reverse	TGTCAGGGTAATAAACACCCACGT
	Probe	CAGAACTCAATCATACACTAATTCTTTTAC (5' FAM or HEX/ZEN/3' IBFQ)
S:477-505	Forward	CTATCAGGCCGGTAACAAAC
	Reverse	ACTACTCTGTATGGTTGGTGAC
	Probe	CCTTTACGATCATATRGTTTCCGACCC 5' FAM or HEX/ZEN/3' IBFQ)


366
367
368
369
370
371
372
373

Table 1. Primers and probes for new mutation assays. Primers and probes for other assays that are previously published are in Table S5. Information on the fluorescent molecule and quenchers used for the probes are provided in parentheses after their sequence. FAM, 6-fluorescein amidite; HEX, hexachloro-fluorescein; ZEN, a proprietary internal quencher from IDT; IBFQ, Iowa Black FQ.


374



375
376 **Figure 1.** Concentrations of N, del143-145, LPPA24S, and S:477-505 at 8 POTWs in the study
377 (name indicated in corner). Error bars are 68% confidence intervals that include error from
378 variation among 10 replicate wells, and Poisson error (“total error” as reported by the
379 instrument). If error bars cannot be seen, they are smaller than the symbol.
380



381
382 **Figure 2.** Relative concentrations of del143-145 and LPPA24S (their concentrations normalized
383 by the N gene) at 8 POTWs in the study (name indicated in corner). Markers are raw ratio
384 values. Lines represent 5-day trimmed moving averages.
385
386
387
388



389
 390 Figure 3. Percentage of clinical cases in California classified as indicated BA.1* and BA.2* as a
 391 function of specimen collection date; data represent 7-d moving average as acquired from
 392 GISAID. Data available through 13 April when downloaded from GISAID on 21 April 2022. Gray
 393 area represents the time period for which data were incomplete on 14 April 2022, when
 394 wastewater measurements for the last date in our data series (12 or 13 April 2022) were
 395 available.